| Product Code: ETC7917173 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Latvia Onco-hematology Molecular Testing Market Overview |
3.1 Latvia Country Macro Economic Indicators |
3.2 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, 2021 & 2031F |
3.3 Latvia Onco-hematology Molecular Testing Market - Industry Life Cycle |
3.4 Latvia Onco-hematology Molecular Testing Market - Porter's Five Forces |
3.5 Latvia Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Type, 2021 & 2031F |
3.6 Latvia Onco-hematology Molecular Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.7 Latvia Onco-hematology Molecular Testing Market Revenues & Volume Share, By Blood Cancer Biomarker, 2021 & 2031F |
3.8 Latvia Onco-hematology Molecular Testing Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Latvia Onco-hematology Molecular Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer and hematological disorders in Latvia |
4.2.2 Technological advancements in molecular testing leading to more accurate and efficient diagnostics |
4.2.3 Growing awareness about the benefits of early detection and personalized treatment in onco-hematology |
4.3 Market Restraints |
4.3.1 High costs associated with molecular testing procedures |
4.3.2 Limited access to advanced molecular testing technologies in some regions of Latvia |
5 Latvia Onco-hematology Molecular Testing Market Trends |
6 Latvia Onco-hematology Molecular Testing Market, By Types |
6.1 Latvia Onco-hematology Molecular Testing Market, By Blood Cancer Type |
6.1.1 Overview and Analysis |
6.1.2 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Blood Cancer Type, 2021- 2031F |
6.1.3 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Chronic Myeloid Leukemia, 2021- 2031F |
6.1.4 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Myeloproliferative Neoplasms, 2021- 2031F |
6.1.5 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Acute Myeloid Leukemia, 2021- 2031F |
6.1.6 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Acute Lymphoblastic Leukemia, 2021- 2031F |
6.2 Latvia Onco-hematology Molecular Testing Market, By Technology |
6.2.1 Overview and Analysis |
6.2.2 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By qPCR, 2021- 2031F |
6.2.3 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By dPCR, 2021- 2031F |
6.2.4 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Next-Generation Sequencing, 2021- 2031F |
6.2.5 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Latvia Onco-hematology Molecular Testing Market, By Blood Cancer Biomarker |
6.3.1 Overview and Analysis |
6.3.2 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By BCR-ABL1 Mbcr, 2021- 2031F |
6.3.3 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By JAK2, 2021- 2031F |
6.3.4 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By CALR, 2021- 2031F |
6.3.5 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By MPL, 2021- 2031F |
6.3.6 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By PML-RARA, 2021- 2031F |
6.3.7 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By NPM1, 2021- 2031F |
6.3.8 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By CBFB-MYH11, 2021- 2031F |
6.3.9 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By CBFB-MYH11, 2021- 2031F |
6.4 Latvia Onco-hematology Molecular Testing Market, By End-user |
6.4.1 Overview and Analysis |
6.4.2 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By National Reference Lab / Specialty Lab, 2021- 2031F |
6.4.3 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By University Hospital / Oncology Center, 2021- 2031F |
6.4.4 Latvia Onco-hematology Molecular Testing Market Revenues & Volume, By Community Hospital / IDN (Regional/National), 2021- 2031F |
7 Latvia Onco-hematology Molecular Testing Market Import-Export Trade Statistics |
7.1 Latvia Onco-hematology Molecular Testing Market Export to Major Countries |
7.2 Latvia Onco-hematology Molecular Testing Market Imports from Major Countries |
8 Latvia Onco-hematology Molecular Testing Market Key Performance Indicators |
8.1 Adoption rate of molecular testing technologies in onco-hematology |
8.2 Rate of increase in early detection of cancer and hematological disorders |
8.3 Number of research and development collaborations in the field of onco-hematology molecular testing |
9 Latvia Onco-hematology Molecular Testing Market - Opportunity Assessment |
9.1 Latvia Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Type, 2021 & 2031F |
9.2 Latvia Onco-hematology Molecular Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.3 Latvia Onco-hematology Molecular Testing Market Opportunity Assessment, By Blood Cancer Biomarker, 2021 & 2031F |
9.4 Latvia Onco-hematology Molecular Testing Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Latvia Onco-hematology Molecular Testing Market - Competitive Landscape |
10.1 Latvia Onco-hematology Molecular Testing Market Revenue Share, By Companies, 2024 |
10.2 Latvia Onco-hematology Molecular Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here